A brief overview of amyloids and Alzheimer's disease

Protein Science

Volumn 23, Issue 10, 2014, Pages 1315-1331

  Ow, Sian Yang ^a   Dunstan, Dave E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's disease; amyloid fibrils; fibril structure; review

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; BETA SECRETASE INHIBITOR; CURCUMIN; GAMMA SECRETASE INHIBITOR; GENISTEIN; PHYSOSTIGMINE; PROTEIN INHIBITOR; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; HUMAN; KINETICS; NANOTECHNOLOGY; NONHUMAN; PHAGOCYTOSIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SYMPTOM; UBIQUITINATION; CHEMICAL STRUCTURE; CHEMISTRY; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; PROTEIN SECONDARY STRUCTURE;

ALZHEIMER DISEASE; AMYLOID; AMYLOIDOSIS; GENE EXPRESSION REGULATION; HUMANS; MODELS, MOLECULAR; PROTEIN STRUCTURE, SECONDARY;

EID: 84928940921     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.2524     Document Type: Review

References (125)

1. Fändrich M, (2007) On the structural definition of amyloid fibrils and other polypeptide aggregates. Cell Mol Life Sci 64: 2066-2078.
2. Kyle RA, (2001) Amyloidosis: a convoluted story. British J Haematol 114: 529-538.
3. Möller HJ, Graeber MB, (1998) The case described by Alois Alzheimer in 1911. Eur Arch Psych Clin Neurosci 248: 111-122.
4. Citron M, (2004) Strategies for disease modification in Alzheimer's Disease. Nature Rev 5: 677-685.
5. Matagne A, Dobson CM, (1998) The folding process of hen lysozyme: a perspective from the 'new view'. CellMol Life Sci 54: 363-371.
6. Dobson CM, (2003) Protein folding and misfolding. Nature 426: 884-890.
7. Stefani M, (2004) Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim Biophys Acta 1739: 5-25.
8. Findeis MA, Musso GM, Arico-Muendel CC, Benjamin HW, Hundal AM, Lee J-J, Joseph Chin MK, Wakefield J, Hayward NJ, Molineaux SM, (1999) Modified-peptide inhibitors of amyloid β-peptide polymerization. Biochemistry 38: 6791-6800.
9. Nielsen L, Khurana R, Coats A, Frokjaer S, Brange J, Vyas S, Uversky VN, Fink AL, (2001) Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 40: 6036-6046.
10. Morozova-Rochea LA, Zurdo J, Spencera A, Noppe W, Receveur V, Archer DB, Joniau M, Dobson CM, (2000) Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants. J Struct Biol 130: 339-351.
11. Pepys MB, (2006) Amyloidosis. Ann Rev Med 57: 223-241.
12. Makin OS, Atkins E, Sikorski P, Johansson J, Serpell LC, (2005) Molecular basis for amyloid fibril formation and stability. Proc Natl Acad Sci USA 102: 315-320.
13. Zandomeneghi G, Krebs MRH, Mccammon MG, Fändrich M, (2004) FTIR reveals structural differences between native β-sheet proteins and amyloid fibrils. Protein Sci 13: 3314-3321.
14. Gharibyan AL, Zamotin V, Yanamandra K, Moskaleva OS, Margulis BA, Kostanyan IA, Morozova-Roche LA, (2007) Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. J Mol Biol 365: 1337-1349.
15. Peter T., Lansbury J, (1999) Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci USA 96: 3342-3344.
16. Jimenez JL, Nettleton EJ, Bouchard M, Robinson CV, Dobson CM, Saibil HR, (2002) The protofilament structure of insulin amyloid fibrils. Proc Natl Acad Sci USA 99: 9196-9201.
17. Wilson MR, Yerbury JJ, Poon S, (2008) Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Mol BioSyst 4: 42-52.
18. Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R, (2002) A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 99: 16742-16747.
19. Lührs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Döbeli H, Schubert D, Riek R, (2005) 3D structure of Alzheimer's amyloid-β(1-42) fibrils. Proc Natl Acad Sci USA 102: 17342-17347.
20. Hamley IW, (2012) The amyloid beta peptide: A chemist's perspective. Role in Alzheimer's and fibrillization. Chem Rev 112: 5147-5192.
21. Nelson R, Eisenberg D, (2006) Recent atomic models of amyloid fibril structure. Curr Opin Struct Biol 16: 260-265.
22. Adamcik J, Jung J-M, Flakowski J, De Los Rios P, Dietler G, Mezzenga R, (2010) Understanding amyloid aggregation by statistical analysis of atomic force microscopy images. Nat Nano 5: 423-428.
23. Adamcik J, Mezzenga R, (2011) Proteins fibrils from a polymer physics perspective. Macromolecules 45: 1137-1150.
24. Gazit E, (2002) A possible role for π-stacking in the self-assembly of amyloid fibrils. FASEB J 16: 77-83.
25. Senguen FT, Doran TM, Anderson EA, Nilsson BL, (2011) Clarifying the influence of core amino acid hydrophobicity, secondary structure propensity, and molecular volume on amyloid-[small beta] 16-22 self-assembly. Mol BioSyst 7: 497-510.
26. Senguen FT, Lee NR, Gu X, Ryan DM, Doran TM, Anderson EA, Nilsson BL, (2011) Probing aromatic, hydrophobic, and steric effects on the self-assembly of an amyloid-[small beta] fragment peptide. Mol BioSyst 7: 486-496.
27. Höyer W, Gronwall C, Jonsson A, Ståhl S, Härd T, (2008) Stabilization of a ß-hairpin in monomeric Alzheimer's amyloid-ß peptide inhibits amyloid formation. Proc Natl Acad Sci USA 105: 5099-5104.
28. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P, (2002) How cells read the genome: from DNA to protein. Molecular biology of the cell. New York, USA (Garland science), pp 355-364.
29. Knauer MF, Soreghan B, Burdick D, Kosmoski J, Galbe CG, (1992) Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/ß protein. Proc Natl Acad Sci USA 89: 7437-7441.
30. Soto C, Castano EM, (1996) The conformation of Alzheimer's ß peptide determines the rate of amyloid formation and its resistance to proteolysis. Biochem J 314: 701-707.
31. Tennent GA, Lovat LB, Pepys MB, (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 92: 4299-4303.
32. Yoshimura Y, Yuxi Lin HY, Lee Y-H, Kitayama H, Sakurai K, So M, Ogi H, Naki H, Goto Y, (2012) Distinguishing crystal-like amyloid fibrils and glass-like amorphous aggregates from their kinetics of formation. Proc Natl Acad Sci USA 109: 14446-14451.
33. Lee S, Fernandez EJ, Good TA, (2007) Role of aggregation conditions in structure, stability, and toxicity of intermediates in the Aß fibril formation pathway. Protein Sci 16: 723-732.
34. Hamilton-Brown P, Bekard I, Ducker WA, Dunstan DE, (2008) How does shear affect Abeta fibrillogenesis? J Phys Chem B 112: 16249-16252.
35. Bekard IB, Dunstan DE, (2009) Shear-induced deformation of bovine insulin in couette flow. J Phys Chem B 113: 8453-8457.
36. Petkova AT, Leapman RD, Guo Z, Yau W-M, Mattson MP, Tycko R, (2005) Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. Science 307: 262-265.
37. White DA, Buell AK, Knowles TPJ, Welland ME, Dobson CM, (2010) Protein aggregation in crowded environments. J Am Chem Soc 132: 5170-5175.
38. Fung J, Darabie AA, McLaurin J, (2005) Contribution of simple saccharides to the stabilization of amyloid structure. Biochem Biophys Res Commun 328: 1067-1072.
39. Bravo R, Arimon M, Valle-Delgado JJ, García R, Durany Nr, Castel S, Cruz M, Ventura S, Ferna'ndez-Busquets X, (2008) Sulfated polysaccharides promote the assembly of amyloid ß1-42 peptide into stable fibrils of reduced cytotoxicity. J Biol Chem 283: 32471-32483.
40. Jiménez JL, Tennent G, Pepys M, Saibil HR, (2001) Structural diversity of ex vivo amyloid fibrils studied by cryo-electron microscopy. J Mol Biol 311: 241-247.
41. Chiti F, Webster P, Taddei N, Clark A, Ramponi MSG, Dobson CM, (1999) Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci USA 96: 3590-3594.
42. Harrison PM, Chan HS, Prusiner SB, Cohen FE, (2001) Conformational propagation with prion-like characteristics in a simple model of protein folding. Protein Sci 10: 819-835.
43. Takeda T, Klimov DK, (2008) Temperature-induced dissociation of Aβ monomers from amyloid fibril. Biophys J 95: 1758-1772.
44. Vestergaard B, Groenning M, Roessle M, Kastrup JS, Weert Mvd, Flink JM, Frokjaer S, Gajhede M, Svergun DI, (2007) A helical structural nucleus is the primary elongating unit of insulin amyloid fibrils. PLOS Biol 5: 1089-1097.
45. Redecke L, Binder S, Elmallah MIY, Broadbent R, Tilkorn C, Schulz B, May P, Goos A, Eich A, Rübhausen M, Betzel C, (2009) UV-light-induced conversion and aggregation of prion proteins. Free Rad Biol Med 46: 1353-1261.
46. O'Nuallain B, Shivaprasad S, Kheterpal I, Wetzel R, (2005) Thermodynamics of Aβ(1-40) amyloid fibril elongation. Biochemistry 44: 12709-12718.
47. Lee C-C, Nayak A, Sethuraman A, Belfort G, McRae GJ, (2007) A three-stage kinetic model of amyloid fibrillation. Biophys J 92: 3448-3458.
48. Morris, AM, Watzky MA, Agar JN, Finke RG, (2008) Fitting neurological protein aggregation kinetic data via a 2-step minimal/Ockham's Razor model: the Finke-Watzky mechanism of nucleation followed by autocatalytic surface growth. Biochemistry 47: 2413-2427.
49. RamiÇrez-Alvarado M, Merkel JS, Regan L, (2000) A systematic exploration of the influence of the protein stability on amyloid fibril formation in vitro. Proc Natl Acad Sci USA 97: 8979-8984.
50. Gursky O, Aleshkov S, (2000) Temperature-dependent β-sheet formation in β-amyloid Aβ1-40 peptide in water: uncoupling β-structure folding from aggregation. Biochim Biophys Acta 1476: 93-102.
51. Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE, (1994) Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science 264: 1464-1467.
52. House E, Collingwood J, Khan A, Korchazkina O, Berthonc G, Exley C, (2004) Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Aβ42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J Alzheimer's Dis 6: 291-301.
53. Seri KPT, Berlepsch Hv, Griebel J, Kirmse R, Böttcher C, Koksch B, (2008) How metal ions affect amyloid formation: Cu2+- and Zn2+-sensitive peptides. ChembioChem 9: 531-536.
54. Humblet-Hua N-P, Sagis LMC, Linden EVD, (2008) Effects of flow on hen egg white lysozyme (HEWL) fibril formation: length, distribution, flexibility and kinetics. J Agricult Food Chem 56: 11875-11882.
55. Xue W-F, Homans SW, Radford SE, (2008) Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly. Proc Natl Acad Sci USA 105: 8926-8931.
56. Oboroceanu D, Wang L, Brodkorb A, Magner E, Auty MAE, (2010) Characterization of β-lactoglobulin fibrillar assembly using atomic force microscopy, polyacrylamide gel electrophoresis, and in situ Fourier transform infrared spectroscopy. J Agric Food Chem 58: 3667-3673.
57. Naiki H, Hashimoto N, Suzuki S, Kimura H, Nakakuki K, Gejyo F, (1997) Establishment of a kinetic model of dialysis-related amyloid fibril extension in vitro. Int J Exp Clin Invest 4: 223-232.
58. Naiki H, Gejyo F,. Kinetic analysis of amyloid fibril formation. In:, Ronald W, Ed. (1999) Methods in enzymology. San Diego, USA (Academic Press), pp 305-318.
59. Krebs MRH, Morozova-Roche LA, Daniel K, Robinson CV, Dobson CM, (2004) Observation of sequence specificity in the seeding of protein amyloid fibrils. Protein Sci 13: 1933-1938.
60. Krebs MRH, Wilkins DK, Chung EW, Pitkeathly MC, Chamberlain AK, Zurdo J, Robinson CV, Dobson CM, (2000) Formation and seeding of amyloid fibrils from wild-type hen lysozyme and a peptide fragment from the β-domain. J Mol Biol 300: 541-549.
61. Harper JD, Peter T., Lansbury J, (1997) Models of amyloid seeding in Alzheimer's disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Ann Rev Biochem 66: 385-407.
62. Hill SE, Miti T, Richmond T, Muschol M, (2011) Spatial extent of charge repulsion regulates assembly pathways for lysozyme amyloid fibrils. PLoS One 6: 1-12.
63. Plakoutsi G, Taddei N, Stefani M, Chiti F, (2004) Aggregation of the acylphosphatase from Sulfolobus solfataricus: The folded and partially unfolded states can both be precursors for amyloid formation. J Biol Chem 279: 14111-14119.
64. Rovio S, Kåreholt I, Helkala E-L, Viitanen M, Winblad B, Tuomilehto J, Soininen H, Nissinen A, Kivipelto M, (2005) Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol 4: 705-711.
65. Graves AB, Duijn CMV, Chandra V, Fratiglioni L, Heyman A, Jorm AF, Kokmen E, Kondo K, Mortimer JA, Rocca WA, Shalat SL, Soininen H, Hofman A, (1991) Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. Intl J Epidemiol 20: S48-S57.
66. Selkoe DJ, (1994) Normal and abnormal biology of the β-amyloid precursor protein. Ann Rev Neuro 17: 489-517.
67. Malchiodi-Albedi F, Contrusciere V, Raggi C, Fecchi K, (2010) Lipid raft disruption protects mature neurons against amyloid oligomer toxicity. Biochim Biophys Acta 1802: 406-415.
68. Glabe CG, Kayed R, (2006) Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neuorology 66: S74-S78.
69. Williams TL, Serpell LC, (2011) Membrane and surface interactions of Alzheimer's Aβ peptide-insights into the mechanism of cytotoxicity. FEBS J 278: 3905-3917.
70. Lee C-C, Sun Y, Huang HW, (2012) How type II diabetes-related islet amyloid polypeptide damages lipid bilayers. Biophys J 102: 1059-1068.
71. Butterfield SM, Lashuel HA, (2010) Amyloidogenic protein-membrane interactions: mechanistic insight from model systems. Angew Chem Intl Ed 49: 5628-5654.
72. Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE, (2003) A cell surface receptor complex for fibrillar β-amyloid mediates microglial activation. J Neurol 23: 2665-2674.
73. Sousa MM, Yan SD, Fernandas R, Guimarães A, Stern D, Saraiva MJ, (2001) Familial amyloid polyneuropathy: Receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurol 21: 7576-7586.
74. Butterfield DA, Drake J, Pocernich C, Castegna A, (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide. Trends Mol Med 7: 548-554.
75. Dember LM, (2006) Amyloidosis-associated kidney disease. J Am Soc Nephrol 17: 3458-3471.
76. Roberts WC, Waller BF, (1983) Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. Am J Cardiol 52: 137-146.
77. Siqueira-Filho AG, Cunha CLP, Tajik AJ, Seward JB, Schattenberg TT, Giuliani ER, (1981) M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 63: 188-196.
78. Hill AF, Desbruslais M, Joiner S, Sidle KCL, Gowland I, Collinge J, Doey LJ, Lantos P, (1997) The same prion strain causes vCJD and BSE. Nature 389: 448-450.
79. Scott MR, Will R, Ironside J, Nguyen H-OB, Tremblay P, DeArmond SJ, Prusiner SB, (1999) Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci USA 96: 15137-15142.
80. Hardy J, Allsop D, (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12: 383-388.
81. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M, (2010) Alzheimer's disease: clinical trials and drug development. Lancet Neurol 9: 702-716.
82. Kidd M, (1963) Paired helical filaments in electron microscopy of Alzheimer's disease. Nature 197: 192-193.
83. Lalonde R, Fukuchi K, Strazielle C, (2012) APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD). Neuro Biobehav Rev 36: 1357-1375.
84. Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings W Jr, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P, (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6: 734-746.
85. Elio S, Philip S, Howard F, (2003) Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2: 539-547.
86. Sugimoto H, (2008) The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis. Chemico-Biological Interact 175: 204-208.
87. Paola D, Domenicotti C, Nitti M, Vitali A, Borghi R, Cottalasso D, Zaccheo D, Odetti P, Strocchi P, Marinari UM, Tabaton M, Pronzato MA, (2000) Oxidative stress induces increase in intracellular amyloid β-protein production and selective activation of βI and βII PKCs in NT2 cells. Biochem Biophys Res Commun 268: 642-646.
88. Braak H, Braak E, (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259.
89. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li Q-X, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL, (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease. Arch Neurol 60: 1685-1691.
90. Solomon B, Koppel R, Hanan E, Katzav T, (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc Natl Acad Sci USA 93: 452-455.
91. Wood SJ, Mackenzie L, Maleeff B, Hurtle MR, Wetzel R, (1996) Selective inhibiton of Aβ fibril formation. J Biol Chem 271: 4086-4092.
92. Wang SS-S, Chen Y-T, Chou S-W, (2005) Inhibition of amyloid fibril formation of β-amyloid peptides via the amphiphilic surfactants. Biochim Biophys Acta 1741: 307-313.
93. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherazi A, Sowell BB, Aisen PS, Thai LJ, (2008) Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in alzheimer disease. Arch Neurol 65: 1031-1038.
94. C. Nereliusa, Sandegren A, Sargsyan H, Raunak R, Leijonmarck H, Chatterjee U, Fisahn A, Imarisio S, Lomas DA, Crowther DC, mberg RS, Johansson J, (2009) alpha-Helix targeting reduces amyloid-ß peptide toxicity. Proc Natl Acad Sci USA 106: 9191-9196.
95. Uversky VN, (2002) Natively unfolded proteins: a point where biology waits for physics. Protein Sci 11: 739-756.
96. Kimov DK, Thirumalai D, (2003) Dissecting the assembly of Aβ16-22 amyloid peptides into antiparallel β sheets. Structure 11: 295-307.
97. Kopan R, Ilagan MXG, (2004) [gamma]-Secretase: proteasome of the membrane? Nat Rev Mol Cell Biol 5: 499-504.
98. Maloney B, Lahiri DK, (2011) The Alzheimer's amyloid β-peptide (Aβ) binds a specific DNA Aβ-interacting domain (AβID) in the APP, BACE1 and APOE promoters in a sequence-specific manner: characterizing a new regulartory motif. Gene 488: 1-12.
99. Johnson VE, Steward W, Smith DH, (2010) Traumatic brain injury and amyloid-β patholoy: a link to Alzheimer's disease? Nat Rev 11: 361-370.
100. Brion JP, Hanger DP, Bruce MT, Couck AM, Flament-Durand J, Anderton BH, (1991) Tau in Alzheimer neurofibrillary tangles. N- and C-terminal regions are differentially associated with paired helical filaments and the location of a putative abnormal phosphorylation site. Biochem J 273: 127-133.
101. Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW, (2005) Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta 1739: 216-223.
102. Braak F, Braak H, Mandelkow EM, (1994) A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol 87: 554-567.
103. Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I, Sjögren M, Wallin A, Xilinas M, Gottfries C-G, (2001) Treatment of Alzheimer's disease with clioquinol. Dement Geriatric Cognit Disord 12: 408-414.
104. Hardy J, Selkoe DJ, (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
105. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO, (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 9: 448-452.
106. Check E, (2002) Nerve inflammation halts trail for Alzheimer's drug. Nature 415: 462.
107. Sinha S, Lopes DHJ, Du Z, Pang ES, Shanmugam A, Lomakin A, Talbiersky P, Tennstaed A, McDaniel OK, Bakshi R, Kuo P-Y, Ehrmann M, Benedek OGB, Loo JA, Klarner F-G, Schrader T, Wang C, Bitan G, (2011) Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. J Am Chem Soc 133: 16958-16969.
108. Hooper NM, Turner AJ, (2002) The search for alpha-secretase and its potential as a therapeutic approach to Alzheimer s disease. Curr Med Chem 9: 1107-1119.
109. Lichtenthaler SF, (2011) Alpha-secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential. J Neurochem 116: 10-21.
110. Green NS, Foss TR, Kelly JW, (2005) Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc Natl Acad Sci USA 102: 14545-14550.
111. Williams P, Sorribas A, Howes M-JR, (2011) Natural products as a source of Alzheimer's drug leads. Natural Prod Rep 28: 48-77.
112. Nielsen L, Frokjaer S, Carpenter JF, Brange J, (2001) Studies of the structure of insulin fibrils by Fourier transform infrared (FTIR) spectroscopy and electron microscopy. J Pharmacol Sci 90: 29-37.
113. Uversky VN, Garriques LN, Millett IS, Frokjaer S, Brange J, Doniach S, Flink AL, (2003) Prediction of the association state of insulin using spectral parameters. J Pharmacol Sci 92: 847-858.
114. Navarra G, Leone M, Militello V, (2007) Thermal aggregation of β-lactoglobulin in presence of metal ions. Biophys Chem 131: 52-61.
115. Frederikse PH, (2000) Amyloid-like protein structure in mammalian ocular lenses. Curr Eye Res 20: 462-468.
116. Fowler DM, Koulov AV, Balch WE, Kelly JW, (2007) Functional amyloid-from bacteria to humans. Trends Biochem Sci 32: 217-224.
117. Atwood CS, Bowen RL, Smith MA, Perry G, (2003) Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply. Brain Res Rev 43: 164-178.
118. Honig LS, Tang M-X, Albert S, Costa R, Luchsinger J, Manly J, Stern Y, Mayeux I, (2003) Stroke and the risk of Alzheimer disease. Arch Neurol 60: 1707-1712.
119. True HL, Lindquist SL, (2000) A yeast prion provides a mechanism for genetic variation and phenotypic diversity. Nature 407: 477-483.
120. Scheibel T, Parthasarathy R, Sawick G, Lin X-M, Haeger H, Lindquist SL, (2003) Conducting Nanowires built by controlled self-assembly of amyloid fibers and selective metal deposition. Proc Natl Acad Sci USA 100: 4527-4532.
121. Barrau S, Zhang F, Herland A, Mammo W, Andersson MR, Inganäs O, (2008) Integration of amyloid nanowires in organic solar cells. Appl Phys Lett 93: 023307.
122. Poon S, Easterbrook-Smith SB, Rybchyn MS, Carver JA, Wilson MR, (2000) Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. Biochemistry 39: 15953-15960.
123. Grune T, Merker K, Sandig G, Davies KJA, (2003) Selective degradation of oxidatively modified protein substrates by the proteasome. Biochem Biophys Res Commun 305: 709-718.
124. Fleisher-Berkovich S, Filipovich-Rimon T, Ben-Shmel S, Hulsmann C, Kummer MP, Heneka MT, (2010) Distinct modulation of microglial amyloid β phagocytosis and migration by neuropeptides. J Neuroinflamm 7: 61.
125. Pan X-D, Zhu Y-G, Lin N, Zhang J, Ye Q-Y, Huang H-P, Chen X-C, (2011) Microglial phagocytosis induced by fibrillar β-amyloid is attenuated by oligomeric β-amyloid: implications for Alzheimer's disease. Mol Nerodegen 6: 45.